September 24, 2019
Kissei Pharmaceutical has launched a PIII clinical trial in Japan for the oral spleen tyrosine kinase (SYK) inhibitor fostamatinib for the treatment of chronic immune thrombocytopenia (ITP), the company said on September 20. Under its license pact with US partner...read more